{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:16:22Z","timestamp":1791994582445,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jid.2021.09.013","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T18:19:30Z","timestamp":1635272370000},"page":"1058-1064.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Temporal Outcomes after Rituximab Therapy for Pemphigus Vulgaris"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9463-5976","authenticated-orcid":false,"given":"Napatra","family":"Tovanabutra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1319-3318","authenticated-orcid":false,"given":"Christina E.","family":"Bax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4151-7228","authenticated-orcid":false,"given":"Rui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7958-3186","authenticated-orcid":false,"given":"Carolyn J.","family":"Kushner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9389-7918","authenticated-orcid":false,"given":"Aimee S.","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2021.09.013_bib1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archdermatol.2009.9","article-title":"ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus","volume":"145","author":"Abasq","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2021.09.013_bib2","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jaad.2017.07.012","article-title":"Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab","volume":"77","author":"Albers","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.09.013_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233957","article-title":"Correlation of IgG autoantibodies against acetylcholine receptors and desmogleins in patients with pemphigus treated with steroid sparing agents or rituximab","volume":"15","author":"Bhatia","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2021.09.013_bib4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1046\/j.1365-2133.2002.04838.x","article-title":"Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3","volume":"147","author":"Cheng","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.09.013_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jaad.2011.11.007","article-title":"Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up","volume":"67","author":"Cianchini","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.09.013_bib6","doi-asserted-by":"crossref","first-page":"175ra30","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jid.2021.09.013_bib7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/jid.2014.291","article-title":"Persistence of anti-desmoglein 3 IgG(+) B-cell clones in pemphigus patients over years","volume":"135","author":"Hammers","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.09.013_bib8","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2133.2001.04132.x","article-title":"The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels","volume":"144","author":"Harman","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2021.09.013_bib9","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jid.2018.04.042","article-title":"Large international validation of ABSIS and PDAI pemphigus severity scores","volume":"139","author":"H\u00e9bert","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.09.013_bib10","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamadermatol.2013.6739","article-title":"Durable remission of pemphigus with a fixed-dose rituximab protocol","volume":"150","author":"Heelan","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.09.013_bib11","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2021.09.013_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A\u00a0single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.09.013_bib13","doi-asserted-by":"crossref","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Pemphigus. Nat Rev Dis Primers"},{"key":"10.1016\/j.jid.2021.09.013_bib32","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1001\/jamadermatol.2019.3236","article-title":"Factors associated with complete remission after rituximab therapy for pemphigus","volume":"155","author":"Kushner","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.09.013_bib14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jid.2021.09.013_bib15","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1172\/JCI5252","article-title":"Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris","volume":"103","author":"Mahoney","year":"1999","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jid.2021.09.013_bib16","first-page":"634","article-title":"The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin","volume":"112","author":"Mankarious","year":"1988","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.jid.2021.09.013_bib17","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92253","article-title":"Stat3 regulates desmoglein 3 transcription in epithelial keratinocytes","volume":"2","author":"Mao","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jid.2021.09.013_bib18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/jamadermatol.2020.0290","article-title":"Factors associated with short-term relapse in patients with pemphigus who receive rituximab as first-line therapy: a post hoc analysis of a randomized clinical trial","volume":"156","author":"Mignard","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2021.09.013_bib19","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J\u00a0Amer Acad Dermatol"},{"key":"10.1016\/j.jid.2021.09.013_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2018.02.021","article-title":"Diagnosis and management of pemphigus: recommendations of an international panel of experts","volume":"82","author":"Murrell","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.09.013_bib21","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E","article-title":"Two-sided confidence intervals for the single proportion: comparison of seven methods","volume":"17","author":"Newcombe","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.jid.2021.09.013_bib22","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1074\/jbc.M309000200","article-title":"Pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal effects on keratinocytes","volume":"279","author":"Nguyen","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jid.2021.09.013_bib23","first-page":"347","article-title":"Long-term repopulation of peripheral B-cell subsets after single and repeated rituximab infusions in patients with rheumatoid arthritis","volume":"33","author":"Roll","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jid.2021.09.013_bib24","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1600-0625.2010.01069.x","article-title":"Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients","volume":"19","author":"Schmidt","year":"2010","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2021.09.013_bib25","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1038\/jid.2009.41","article-title":"Pathogenic anti-desmoglein MAbs show variable ELISA activity because of preferential binding of mature versus proprotein isoforms of desmoglein 3","volume":"129","author":"Sharma","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.09.013_bib26","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1111\/jdv.16561","article-title":"Long-term outcomes of rituximab therapy in pemphigus","volume":"34","author":"Shimanovich","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2021.09.013_bib27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1046\/j.1523-1747.1998.00085.x","article-title":"Lack of mucosal involvement in pemphigus foliaceus may be due to low expression of desmoglein 1","volume":"110","author":"Shirakata","year":"1998","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.09.013_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-017-1306-0","article-title":"B\u00a0cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients","volume":"19","author":"Thiel","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jid.2021.09.013_bib29","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jaad.2017.11.024","article-title":"Rituximab as first-line adjuvant therapy for pemphigus: retrospective analysis of long-term outcomes at a single center","volume":"78","author":"Vinay","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2021.09.013_bib30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ejps.2009.02.014","article-title":"Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency","volume":"37","author":"Wasserman","year":"2009","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.jid.2021.09.013_bib31","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa2028564","article-title":"Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris","volume":"384","author":"Werth","year":"2021","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21022922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21022922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:49:08Z","timestamp":1762206548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X21022922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0022202X21022922"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2021.09.013","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741071118.793589523","asserted-by":"object"}]},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temporal Outcomes after Rituximab Therapy for Pemphigus Vulgaris","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2021.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}